BRAVECTO® PLUS at a glance
Fast and easy-to-apply
up to 12-week
protection1
Immediate and persistent flea (Ctenocephalides felis) and tick (Ixodes ricinus) killing activity for up to 12 weeks
Prevents heartworm
disease caused by
Dirofilaria immitis* and lungworm disease caused by Aelurostrongylus abstrusus*
*When administered repeatedly as indicated at 12-weeks intervals.
BRAVECTO® PLUS at a glance
Protection against aelurostrongylosis by preventing the establishment of adult Aelurostrongylus abstrusus (lungworm) responsible for clinical disease.
Extended protection in just one dose makes on-time application simple
The survey has shown that cat owners are more likely to administer fluralaner at the recommended redosing interval compared to monthly products, indicating that
Less frequent redosing contributes to improved adherence2
Cat owner compliance is better with the extended flea and tick protection that BRAVECTO PLUS provides. Fast, easy and lasting protection is the best way to achieve year-round coverage.
Reasons owners may not be protecting their cats from parasites:
- Treating cats can be difficult
- Do not understand or are not aware of the parasite risks
- Forget to give the next dose
BRAVECTO PLUS: Convenient, broad-spectrum protection
BRAVECTO PLUS provides1
Up to 12 weeks flea and tick control
Up to 12 weeks heartworm disease prevention*
Ear mite treatment4
Broad-spectrum worm coverage
Up to 12 weeks aelurostrongylosis (lungworm) prevention5
Reduced dosing frequency for improved adherence2
*When administered repeatedly as indicated at 12-week intervals.
Show fleas, ticks and worms the door all year round
Break the flea life cycle with up to 12 weeks efficacy in one dose1
Efficacy against ticks over 12 weeks1
When administered repeatedly at a 12-week interval, BRAVECTO PLUS continuously prevents heartworm disease caused by Dirofilaria immitis1
Treatment of infections with intestinal roundworm (Toxocara cati; L4, L5 and adults). Treatment of infections with hookworm (Ancylostoma tubaeforme; immature adults and adults)1
100% treatment efficacy against ear mites (Otodectes cynotis)4
Up to 12 weeks prevention of aelurostrongylosis by preventing the establishment of adult Aelurostrongylus abstrusus (lungworm) responsible for clinical disease5
More than flea and tick protection
Fleas and ticks are vectors for many dangerous diseases.3
BRAVECTO PLUS can be used as a treatment strategy for the control of flea allergy dermatitis (FAD).1
BRAVECTO PLUS protection against heartworm
INFECTION
with heartworm
treatment
REPEAT ADMINISTRATION EVERY 12 WEEKS
to continuously prevent heartworm disease
BRAVECTO PLUS offers an innovative approach to heartworm disease prevention with a combination of a 60-day “reach forward” effect that prevents the development of Dirofilaria immitis larvae AND a “reach back” effect, where heartworm larvae entering the cat in the 30 days prior to treatment are effectively removed.6
THE LEADING LONG-LASTING SYSTEMIC FLEA, TICK AND HEARTWORM PREVENTION WITH TREATMENT FOR CERTAIN WORMS AND MITES
Learn how BRAVECTO PLUS outlasts monthly alternatives
Long-lasting protection with just one dose
One dose of BRAVECTO PLUS protects your patient against fleas, ticks and heartworms for up to 12 weeks.1 With four doses* of BRAVECTO PLUS, your patients are protected year round vs 12 doses of a one-month product.
*Based on the labelled dosing, four doses will provide 48 weeks of coverage.
Kills fleas and ticks in hours
BRAVECTO PLUS starts killing fleas (Ctenocephalides felis) and ticks (Ixodes ricinus) within 48 hours of treatment.1
Also approved for kittens
BRAVECTO PLUS for cats is indicated for kittens over nine weeks old and weighing at least 1.2 kg.1
Trusted by millions
Over 300 million doses of BRAVECTO have been distributed around the world.
Broad spectrum parasite protection
12 weeks heartworm disease prevention (Dirofilaria immitus)1, *12 weeks aelurostrongylosis (lungworm) prevention.1 Treats Toxocara cati (intestinal roundworm) and Ancylostoma tubaeforme (hookworm) infections.1 Treats ear mites (Otodectes cynotis).
When administered repeatedly as indicated at 12-week intervals.
What does BRAVECTO PLUS DO for cats?
Just one dose of BRAVECTO PLUS protects your feline patients (and their homes) from the dangers posed by fleas and ticks continuously for up to 12 weeks.1
When administered repeatedly at a 12-week interval, BRAVECTO PLUS prevents heartworm disease caused by
D immitis.1
BRAVECTO PLUS prevents aelurostrongylosis (adult Aelurostrongylus abstrusus are responsible for clinical disease) for up to 12 weeks.1,5
BRAVECTO PLUS also treats infections with Toxocara cati (intestinal roundworm) and Ancylostoma tubaeforme (hookworm)1 as well as ear mites (Otodectes cynotis).
How do I protect my feline patients?
Direct cat owners to give one dose of BRAVECTO PLUS for up to 12 weeks of lasting flea and tick protection. For heartworm treatment, advise cat owners to administer BRAVECTO PLUS at a 12-week interval. BRAVECTO PLUS also provides up to 12 weeks of aelurostrongylosis protection by preventing the establishment of adult Aelurostrongylus abstrusus (lungworm) responsible for clinical disease and can be used to treat infections with gastrointestinal nematodes.1
BRAVECTO IS HERE TO SUPPORT you
We have the tools to help you start the conversation with pet owners about why year-round protection is important.
Be the answer and start sharing BRAVECTO today!
Discover tools for speaking with pet owners.
Do YOU WANT TO KNOW MORE?
Complete the form so we can contact you*
General Contact Information
“*” indicates required fields
PRESCRIBING BRAVECTO PLUS
BRAVECTO PLUS is available for cats weighing 1.2 kg and more. The fumble-free Twist’n’Use™ applicator makes administration easy for Pet Owners. It’s straightforward and, most importantly, pet friendly. The cap does not come off to offer additional safety, leaving no small parts loose for animals or children to accidentally swallow.
FREQUENTLY ASKED QUESTIONS
The following frequently asked questions (FAQs) can help answer additional queries you may have.
Fluralaner is a potent inhibitor of arthropod nervous system function by acting antagonistically on ligand-gated chloride channels (GABA-receptor and glutamate-receptor). These are insect and acarine specific GABA-gated chloride channels (GABACI) and glutamate-gated chloride channels (GluCl). Fluralaner at expected clinical concentrations showed no activity on the mammalian nervous system GABACI receptor.8
Moxidectin is a semisynthetic derivative of nemadectin, belonging to the milbemycin group of macrocyclic lactones (avermectins being the other). Milbemycins and avermectins have a common mode of action that is based on the binding of ligand-gated chloride channels (glutamate-R and GABA-R). This leads to an increased membrane permeability of nematode and arthropod nerve and/or muscle cells for chloride ions and results in hyperpolarisation, paralysis and death of the parasites. Binding of glutamate-gated chloride channels, which are specific to invertebrates and do not exist in mammals, is considered the main mechanism for the anthelmintic and insecticidal activity.
Yes, 9-week-old kittens were treated at doses of up to 465 mg fluralaner and 23.25 mg moxidectin/kg body weight BW with BRAVECTO PLUS spot-on for cats. No adverse reactions were observed following topical administration to kittens.1
Fluralaner and moxidectin, the active ingredients in BRAVECTO PLUS, are readily systemically absorbed from the topical application site. Fluralaner and moxidectin are mainly excreted unchanged in the faeces and to a very low extent in urine. The pharmacokinetic profiles of fluralaner and moxidectin are not affected by co-administration.1
BRAVECTO PLUS is licensed to be used year-round aligning with ESCCAP guidelines to worm cats at least quarterly against Toxocara roundworm.9
BRAVECTO PLUS treats Otodectes cynotis successfully. Both active ingredients have been shown to have efficacy against Otodectes cynotis.
A growing kitten should be dosed with a pipette containing the amount of fluralaner and moxidectin appropriate to the body weight at the time of treatment. The field studies conducted in the EU and the US included growing kittens, and there was no evidence of lack of efficacy. BRAVECTO PLUS showed very good and continuous efficacy, against fleas and ticks, throughout the 12-week interval in these kittens.
BRAVECTO has a high margin of safety. In safety studies in cats, BRAVECTO PLUS (fluralaner + moxidectin) was tested in cats and kittens at up to 5x the recommended dose at 8-week intervals for 3 consecutive treatments. Therefore, adverse effects beyond those reported on the prescribing information are not expected if cats are inadvertently treated twice before the recommended re-treatment interval has elapsed.1
The onset of effect (killing effect) is within 48 hours for fleas and ticks (C felis and I ricinus).1
BRAVECTO first received regulatory approval in early 2016. It is backed by many clinical studies and over 80 published papers.
BRAVECTO PLUS starts to kill fleas within 48 hours of administration. BRAVECTO PLUS kills fleas before they can lay eggs.1
BRAVECTO PLUS prevents heartworm disease caused by Dirofilaria immitis for up to 12 weeks when administered repeatedly at the indicated 12-week interval.1
BRAVECTO PLUS treats aelurostrongylosis by preventing the establishment of adult Aelurostrongylus abstrusus (lungworm) responsible for clinical disease.1
REFERENCES
- BRAVECTO PLUS. Summary of Product Characteristics. https://ec.europa.eu/health/documents/community-register/html/v224.htm
- Lavan, R., et al. (2020). “”Adherence to veterinary recommendations for ectoparasiticides purchased by cat owners in the USA.”” Parasit Vectors 13(1): 541.
- Control of Vector-Borne Diseases in Dogs and Cats ESCCAP Guideline 05 Fourth Edition – January 2023 https://www.esccap.org/uploads/docs/5y4xn3fr_0775_ESCCAP_Guideline_GL5_20221228_1p.pdf
- Taenzler, J., et al. (2018). “”Efficacy of fluralaner plus moxidectin (BRAVECTO® PLUS spot-on solution for cats) against Otodectes cynotis infestations in cats.”” Parasit Vectors 11(1): 595.
- Raue, K., et al. (2021). “”Efficacy of Bravecto((R)) Plus spot-on solution for cats (280 mg/ml fluralaner and 14 mg/ml moxidectin) for the prevention of aelurostrongylosis in experimentally infected cats.”” Parasit Vectors 14(1): 110.
- BRAVECTO PLUS. European Public Assessment Report, 2019. EMA/626816/2019
- Lavan, R. P., et al. (2021). “”Flea and tick treatment satisfaction, preference, and adherence reported by cat owners in the US, UK, or France who treated their cats with transdermal fluralaner.”” Open Vet J 11(3): 458-467.
- Gassel, M., et al. (2014). “”The novel isoxazoline ectoparasiticide fluralaner: selective inhibition of arthropod gamma-aminobutyric acid- and L-glutamate-gated chloride channels and insecticidal/acaricidal activity.”” Insect Biochem Mol Biol 45: 111-124.
- Control of Ectoparasites 3 in Dogs and Cats. ESCCAP Guideline 03 Seventh Edition – January 2022
